{"url_path":"/sec/otlk/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","accession_number":"0001104659-26-068659","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":58,"has_tables":true,"body_markdown":"**Item 8.01**\n**Other Events.**\n\n \n\nOn June 1, 2026, Outlook Therapeutics, Inc (the\n“Company”) issued a press release announcing that it has resubmitted the Biologics License\nApplication for ONS-5010 to the U.S. Food and Drug Administration.\n\n \n\nThe press release is attached as Exhibit 99.1\nto this Current Report on Form 8-K and incorporated into this item 8.01 by reference."}